Skip to main content
. 2023 Aug 25;6(8):e2330885. doi: 10.1001/jamanetworkopen.2023.30885

Figure 1. Risk of Recurrent Gout Flares in Each Month Over 12-Month Period After Initiation of Treatment With Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) or Active Comparators.

Figure 1.

Active comparators consist of glucagonlike peptide-1 receptor agonists or dipeptidyl peptidase-4 inhibitors.